Qiagen

from Wikipedia, the free encyclopedia
QIAGEN NV

logo
legal form Naamloze Vennootschap
ISIN NL0012169213
founding 1984
Seat Venlo , the NetherlandsNetherlandsNetherlands 
management Thierry Bernard ( CEO )
Lawrence A. Rosen (Chairman of the Supervisory Board)
Number of employees 4,952
sales $ 1.502 billion (2018)
Branch biotechnology
Website www.qiagen.com
As of December 31, 2018

The QIAGEN NV is a provider of sample and assay technologies for molecular diagnostics, academic research, pharmaceutical industry and applied testing.

Under the Dutch parent company , QIAGEN has over 35 subsidiaries in over 25 countries.

QIAGEN shares are traded on the US stock exchange NYSE and the German stock exchange in Frankfurt in the Prime Standard and are included in the TecDAX and since September 24, 2018 also in the MDAX . The company's Chief Executive Officer is Thierry Bernard following the resignation of Peer M. Schatz . The operational headquarters are in Hilden near Düsseldorf. The holding company is based in Venlo , the Netherlands .

history

Today's society was founded on November 29, 1984 by a team of scientists from the University of Düsseldorf as the Diagen Institute for Molecular Diagnostics . The beginning of QIAGEN's business activity marked the development of new methods for the purification of nucleic acids as carriers of genetic information. In order to be able to work with different molecules of a cell such as nucleic acids (DNA and RNA) and proteins, these must be separated from other cell components and purified. The discovery cut the preparation time for plasmids , small circular DNA molecules of a bacterial cell, from two to three days to two hours.

Diagen received venture capital and A. von Matuschkas TVM (Techno Venture Management) .

Further milestones in the development of the company were the listing on the US technology exchange NASDAQ in 1996 as the first German company to date and the founding of the holding company QIAGEN NV in Venlo, the Netherlands, in the same year . In the following year, it was listed on the Frankfurt Stock Exchange.

Sales rose to 466 million US dollars in 2006, the number of employees grew to more than 2600. In June 2007, the takeover of "Digene Corp." took place for around 1.6 billion US dollars. With this, QIAGEN established itself as a provider in the market for molecular diagnostics. Other strategically important acquisitions included the takeover of the British DxS Ltd. in Manchester in 2009 and thus the expansion of the product range to include companion diagnostics for personalized medicine as well as the Australian company Cellestis in 2011 and a method for the detection of latent tuberculosis.

At the end of 2011, QIAGEN announced that it would cut 300 to 380 of the approximately 3800 jobs worldwide as part of a comprehensive restructuring program. At the end of 2018, there were almost 5,000 employees worldwide.

In 2013, QIAGEN expanded its business activities to include bioinformatics with the acquisition of the software companies Ingenuity Systems and CLC bio . The acquisitions are related to the development of its own system solution for gene sequencing, with which QIAGEN specifically targets the diagnostic market.

In early 2015, QIAGEN announced that it had acquired the Enzyme Solutions business unit from Enzymatics. With this acquisition, QIAGEN acquired extensive skills to implement its strategy of offering a complete workflow for next generation sequencing .

In November 2015, QIAGEN presented the GeneReader NGS system , the world's first complete workflow for next-generation sequencing, which covers all work steps from preparing the primary sample to creating a final report.

On January 10, 2018, QIAGEN switched its listing from the US stock exchange NASDAQ to the NYSE . In April 2018, QIAGEN took over the Spanish diagnostics company STAT-Dx and presented the QIAstat-Dx based on the acquired technology. In September the company announced a partnership with NeuMoDx to commercialize a PCR automation platform.

In 2019, QIAGEN announced the acquisition of Formulatrix facilities to develop a digital PCR platform. Another acquisition was that of N-of-One, a privately held US molecular decision support company that pioneered the clinical interpretation of complex genomic data to add Real World Insights to QCI bioinformatics .

On March 3, 2020, it was announced that Thermo Fisher Scientific intended to acquire Qiagen. At least 75% of the shares should be bought at 39 €, approx. 23% above the market price at the time. The offer was supported by the Qiagen Management Board and Supervisory Board. The offer was later increased to € 43 and the acceptance threshold lowered to 66.66%. The takeover offer expired on August 10, 2020, by which time only 47.02% of the shares had been offered. Qiagen then had to pay Thermo Fisher a reimbursement of US $ 95 million.

Products

QIAGEN's range of products today includes sample preparation and test technologies as well as automation processes for these technologies. These include reagents, laboratory robots and software solutions for bioinformatics. With these products, the company serves the markets for molecular diagnostics, academic research, the pharmaceutical industry and applied test procedures. According to its own information, QIAGEN has the broadest portfolio of molecular test technologies, which are offered in the form of open detection kits and tests with fixed test objectives. In total, the company's product range comprises more than 500 products. Over 1,000 patents are registered in the name of QIAGEN.

Areas of application and application examples

In the area of ​​molecular diagnostics, QIAGEN's test technologies are used by customers in hospitals and medical laboratories to identify diseases or infections based on their genetic traces and to use this evidence to develop therapies. QIAGEN offers around 120 different tests that can be used to detect viruses, bacteria, parasites as well as genetic and pharmacogenetic characteristics.

Sample preparation and test technologies from QIAGEN can also be used in the market for applied test procedures, i.e. in veterinary medicine, forensics or food control. Areas of application include a. Perpetrator and victim identification (forensics), the preparation of parentage reports, food and drinking water monitoring and protection against biological warfare agents. In the field of veterinary medicine, the company offers tests and test components for the detection of bird flu viruses ( influenza A virus H5N1 ) and other pathogens.

Web links

Individual evidence

  1. ↑ a b c Annual Report 2018 , accessed on March 15, 2019
  2. ↑ QIAGEN: QIAGEN reports results for the first quarter of 2016. In: www.qiagen.com. Retrieved April 29, 2016 .
  3. ↑ Biotech company: Qiagen transfers stock trading to Wall Street . ( handelsblatt.com [accessed January 15, 2018]).
  4. ↑ Changes in the indices ( English , PDF) Deutsche Börse . September 5, 2018. Archived from the original on September 6, 2018. Info: The archive link has been inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. Retrieved September 5, 2018. @1@ 2Template: Webachiv / IABot / deutsche-boerse.com
  5. ↑ QIAGEN announces CEO leadership transition. In: corporate.qiagen.com. Retrieved October 8, 2019 .
  6. ↑ QIAGEN NV: Contacts: Operative Headquarters Retrieved February 14, 2018.
  7. ↑ biospektrum.de: QIAGEN - From start-up to internationally established company , 4/2004
  8. ↑ QIAGEN NV: QIAGEN Announces Acquisition of Digene - Creation of Market and Technology Leader in Molecular Diagnostics. June 3, 2007, accessed May 10, 2010 .
  9. ↑ Pharmaceutical Industry - We need leaders . In: Der Spiegel . No. 24 , 2007 ( online ).
  10. ↑ QIAGEN Acquires DxS Ltd - Creating Leadership in Personalized Healthcare . Retrieved February 6, 2014.
  11. ↑ QIAGEN completes acquisition of Cellestis Limited . Retrieved February 6, 2014.
  12. ↑ Thomson Reuters: QIAGEN wants to cut up to ten percent of its jobs. November 29, 2011, accessed December 6, 2011 .
  13. ↑ QIAGEN Acquires CLC Bio . Retrieved February 6, 2014.
  14. ↑ QIAGEN Buys Ingenuity Systems, Biology Software Player, for $ 105M . Retrieved February 6, 2014.
  15. ↑ QIAGEN Reports Third Quarter 2013 Results
  16. ↑ QIAGEN: QIAGEN acquires the Enzyme Solutions business from Enzymatics, a leading provider of NGS applications. In: www.qiagen.com. Retrieved April 29, 2016 .
  17. ↑ QIAGEN: QIAGEN introduces GeneReader NGS system. In: www.qiagen.com. Retrieved April 29, 2016 .
  18. ↑ Handelsblatt: Biotech company QIAGEN transfers stock trading to Wall Street. In: www.handelsblatt.com. Retrieved January 15, 2018 .
  19. ↑ labiotech: Qiagen Snaps Up a Spanish Biotech. In: www.labiotech.eu. Retrieved January 16, 2019 .
  20. ↑ wallstreet-online: QIAGEN and NeuMoDx announce strategic partnership. In: www.wallstreet-online.de. Retrieved January 16, 2019 .
  21. ↑ The shareholder: Qiagen starts the new year with a flood of news - SHAREHOLDER recommendation is over 60 percent in front. In: www.deraktionaer.de. Retrieved March 18, 2019 .
  22. ↑ QIAGEN shares shoot up: Thermo Fisher presents takeover bid for QIAGEN. In: finanzen.net. March 3, 2020, accessed March 4, 2020 .
  23. ↑ Thermo Fisher increases offer for Qiagen - investor demands more. In: handelsblatt.com. July 17, 2020, accessed August 14, 2020 .
  24. ↑ Solinger Tageblatt of August 14, 2020, page 12
  25. ↑ Largest takeover in the German biotech industry has failed. In: handelsblatt.com. August 13, 2020, accessed on August 14, 2020 .

Coordinates: 51 ° 10 ′ 10.2 ″  N , 6 ° 59 ′ 0.6 ″  E